Market Newsdesk

SUFFOLK, Va., April 23, 2026 (GLOBE NEWSWIRE) — TowneBank (NASDAQ: TOWN) announced today that its Board of Directors declared a onetime special dividend of $0.70 per common share payable on May 20, 2026 to shareholders of record as of the close of business on May 4, 2026.

The total dividend payout of approximately $65 million represents a payment to our shareholders of roughly 32% of the estimated $203 million gain, before taxes and deal costs, recognized by TowneBank on the sale of its Resort Property Management business that was completed on April 3, 2026 for a purchase price of $250 million.

“Throughout the years we have executed on the unique strategy of building intrinsic value for our shareholders through various investments in non-bank businesses. Today’s special dividend is a result of the success of our strategy,” said G. Robert Aston, Jr., Executive Chairman.

The amount and declaration of future cash dividends are subject to Board of Directors’ approval in addition to regulatory restrictions.

About TowneBank:
Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a focus of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, TowneBank operates over 70 banking offices throughout Hampton Roads and Central Virginia, Eastern and Central North Carolina, the Greenville and upstate region of South Carolina, and Charleston, South Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. TowneBank has grown its capabilities beyond banking to provide expertise through its affiliated companies that include Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices RW Towne Realty, Towne 1031 Exchange, and Towne Trust Company, N.A. With total assets of $22.36 billion as of March 31, 2026, TowneBank is one of the largest banks headquartered in Virginia.

Media contact:

G. Robert Aston, Jr., Executive Chairman, 757-638-6780
William I. Foster III, President and Chief Executive Officer, 757-417-6482

Investor contact:

William B. Littreal, Chief Financial Officer, 757-638-6813

MIAMI, April 23, 2026 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report first quarter 2026 financial results on Monday, May 4, 2026 at 6:30 a.m. Eastern Time with a conference call and webcast to discuss results at 8:30 a.m. Eastern Time.

The conference call will be webcast via the Company’s Investor Relations website, https://www.nclhltd.com/investors. A replay of the webcast will be available here on the Company’s website for 30 days following the call.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company that operates Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises. With a combined fleet of 35 ships and more than 75,000 berths, NCLH offers itineraries to approximately 700 destinations worldwide. NCLH expects to add 16 additional ships across its three brands through 2037, which will add ~43,000 berths to its fleet. To learn more, visit www.nclhltd.com.

Investor Relations and Media Contacts
Sarah Inmon (786) 812-3233
[email protected]

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The abstract, entitled “The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study,” explores RenovoRx’s lead product candidate, intra-arterial delivery of gemcitabine via RenovoCath (known as IAG), and its potential to reduce systemic levels of the chemotherapy gemcitabine and increase levels of its inactive metabolite compared with intravenous gemcitabine. Additionally, the abstract studies IAG administration and its direct correlation between the metabolite levels and CA 19-9, a biomarker commonly used to assess potential chemotherapy response.

“This study provides important insights into how targeted intra-arterial delivery of chemotherapy may optimize drug distribution and pharmacologic activity in locally advanced pancreatic cancer,” said Dr. Ramtin Agah, RenovoRx’s Executive Chairman and Chief Medical Officer, and study co-author. “We believe IAG has the potential to enhance effectiveness of therapeutic delivery while reducing systemic toxicity and common side effects.”

The 2026 ASCO Annual Meeting will be held May 29 – June 2, 2026, in Chicago, Illinois, with the online publication of the abstract scheduled for May 21, 2026, at 5:00 P.M. ET.

Abstract Details:

Online Publication Date & Time: May 21, 2026, at 5:00 P.M. ET
Number for Publication: E16463
Title: The TIGeR-PaC Phase III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study. 

About RenovoRx, Inc.

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In its first full year of commercial efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales and learned valuable lessons that will help drive growth in 2026 and beyond. Several customers have already initiated repeat orders and the number of medical institutions initiating new RenovoCath orders is expanding, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations, strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue-generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
[email protected]

Media Contact:

STiR Communications
Hannah Williams
T: 803-521-1214
[email protected]

WEST DES MOINES, Iowa, April 23, 2026 (GLOBE NEWSWIRE) — West Bancorporation, Inc. (Nasdaq: WTBA; the “Company”), parent company of West Bank, today reported first quarter 2026 net income of $10.6 million, or $0.61 per diluted common share, compared to fourth quarter 2025 net income of $7.4 million, or $0.43 per diluted common share, and first quarter 2025 net income of $7.8 million, or $0.46 per diluted common share. On April 22, 2026, the Company’s Board of Directors declared a regular quarterly dividend of $0.25 per common share. The dividend is payable on May 20, 2026, to stockholders of record on May 6, 2026.

David Nelson, President and Chief Executive Officer of the Company, commented, “Our priorities continue to center on our relationship building strategies to drive improvements in profitability and build shareholder value. Our net interest margin continues to expand and we saw net income increase 34.8 percent in the first quarter of 2026 compared to the first quarter of 2025. Our teams are working hard at the activities that we believe will result in enhanced financial performance.”

Mr. Nelson added, “Our balance sheet remains exceptionally strong, supported by solid capital and liquidity levels. Credit quality remains pristine with no loans on nonaccrual status at March 31, 2026. Additionally, this marks our seventh consecutive quarter-end with no loans greater than 30 days past due.”

First Quarter 2026 Compared to Fourth Quarter 2025 Overview

• Loans decreased $10.1 million, or 0.3 percent, in the first quarter of 2026. We continue to experience notable loan payoffs as a result of secondary market refinancings and asset and business sales. The change in loan mix is primarily due to reclassifications resulting from completed construction projects moving to permanent financing and commercial loan restructurings adding real estate collateral.
• No credit loss expense on loans was recorded in either the first quarter of 2026 or fourth quarter of 2025.
• The allowance for credit losses to total loans was 1.02 percent as of both March 31, 2026 and December 31, 2025. There were no nonaccrual loans at March 31, 2026 or December 31, 2025. Watch list loans decreased from $52.2 million as of December 31, 2025 to $41.3 million as of March 31, 2026. This decrease was primarily due to the payoff of one commercial real estate loan in the first quarter of 2026 with a balance of $11.4 million.
• Deposits decreased $133.5 million, or 3.8 percent, in the first quarter of 2026. Brokered deposits totaled $116.5 million at March 31, 2026, compared to $154.6 million at December 31, 2025, a decrease of $38.1 million. Excluding brokered deposits, deposits decreased $95.4 million, or 2.9 percent, during the first quarter of 2026. The decline in deposits was due to normal cash flow fluctuations of our core depositors. As of March 31, 2026, estimated uninsured deposits, which exclude deposits in a reciprocal deposit network, brokered deposits and public funds protected by state programs, accounted for approximately 27.0 percent of total deposits.
• Net interest margin, on a fully tax-equivalent basis (a non-GAAP measure), was 2.59 percent for the first quarter of 2026, compared to 2.47 percent for the fourth quarter of 2025. Net interest income for the first quarter of 2026 was $24.4 million, compared to $24.2 million for the fourth quarter of 2025. The improvement in net interest margin was primarily due to a 14 basis point decrease in the cost of deposits in the first quarter of 2026 when compared to the fourth quarter of 2025.
• The efficiency ratio (a non-GAAP measure) improved to 49.85 percent for the first quarter of 2026, compared to 50.21 percent for the fourth quarter of 2025.

• The tangible common equity ratio was 6.75 percent as of March 31, 2026, compared to 6.42 percent as of December 31, 2025.

First Quarter 2026 Compared to First Quarter 2025 Overview

• Loans decreased $24.8 million at March 31, 2026, or 0.8 percent, compared to March 31, 2025. We continue to experience notable loan payoffs as a result of secondary market refinancings and asset and business sales. The change in loan mix is primarily due to reclassifications resulting from completed construction projects moving to permanent financing and commercial loan restructurings adding real estate collateral.
• Deposits increased $10.5 million, or 0.3 percent, at March 31, 2026, compared to March 31, 2025. Included in deposits were brokered deposits totaling $116.5 million at March 31, 2026, compared to $335.5 million at March 31, 2025. Excluding brokered deposits, deposits increased $229.5 million, or 7.7 percent, as of March 31, 2026, compared to March 31, 2025. In the second quarter of 2025, a local municipal customer deposited approximately $243.0 million of bond proceeds that are expected to be withdrawn over a 24 month time period.
• Net interest margin, on a fully tax-equivalent basis (a non-GAAP measure), was 2.59 percent for the first quarter of 2026, compared to 2.28 percent for the first quarter of 2025. Net interest income for the first quarter of 2026 was $24.4 million, compared to $20.9 million for the first quarter of 2025. The increase in net interest margin and net interest income was primarily due to a decrease in interest expense on deposits and borrowed funds. The cost of deposits decreased by 40 basis points in the first quarter of 2026 compared to the first quarter of 2025. This was partially offset by a $79.8 million increase in average deposit balances in the first quarter of 2026 compared to the first quarter of 2025. Additionally, the average balance of borrowed funds decreased $16.2 million in the first quarter of 2026, compared to the first quarter of 2025.
• The efficiency ratio (a non-GAAP measure) was 49.85 percent for the first quarter of 2026, compared to 56.37 percent for the first quarter of 2025. The improvement in the efficiency ratio in the first quarter of 2026 compared to the first quarter of 2025 was primarily due to the increase in net interest income.

• The tangible common equity ratio was 6.75 percent as of March 31, 2026, compared to 5.97 percent as of March 31, 2025. The increase in the tangible common equity ratio was due to growth in retained earnings and a decrease in accumulated other comprehensive loss.

The Company filed its report on Form 10-Q with the Securities and Exchange Commission today. Please refer to that document for a more in-depth discussion of the Company’s financial results. The Form 10-Q is available on the Investor Relations section of West Bank’s website at www.westbankstrong.com.

The Company will discuss its results in a conference call scheduled for 2:00 p.m. Central Time on Thursday, April 23, 2026. The telephone number for the conference call is 800-715-9871. The conference ID for the conference call is 7846129. A recording of the call will be available until May 7, 2026, by dialing 800-770-2030. The conference ID for the replay call is 7846129 followed by the # key.

About West Bancorporation, Inc. (Nasdaq: WTBA)

West Bancorporation, Inc. is headquartered in West Des Moines, Iowa. Serving customers since 1893, West Bank, a wholly-owned subsidiary of West Bancorporation, Inc., is a community bank that focuses on lending, deposit services, and trust services for small- to medium-sized businesses and consumers. West Bank has six offices in the Des Moines, Iowa metropolitan area, one office in Coralville, Iowa, and four offices in Minnesota in the cities of Rochester, Owatonna, Mankato and St. Cloud.

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to the Company’s business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may appear throughout this report. These forward-looking statements are generally identified by the words “believes,” “expects,” “intends,” “anticipates,” “projects,” “forecasts,” “plans,” “targets,” “future,” “confident,” “potentially,” “probably,” “outlook,” “may,” “should,” “would,” “could,” “will,” “strategy,” “plan,” “opportunity,” “will be,” “will likely result,” “will continue” or similar references, as well as the negative of such words, or references to estimates, predictions or future events. Forward-looking statements are not historical facts but instead represent management’s current expectations and forecasts regarding future events, many of which are inherently uncertain and outside of our control. Such forward-looking statements are based upon certain underlying assumptions, known and unknown, risks and uncertainties. Because of the possibility that the underlying assumptions are incorrect or do not materialize as expected in the future, actual results may differ, possibly materially from these forward-looking statements. Risks and uncertainties that may affect future results include, but are not limited to: interest rate risk, including the effects of changes in interest rates; fluctuations in the values of the securities held in our investment portfolio, including as a result of rising interest rates; competitive pressures, including from non-bank competitors such as credit unions, “fintech” companies and digital asset service providers; technological changes implemented by us and other parties, including third-party vendors, which may be more difficult to implement or more expensive than anticipated or which may have unforeseen consequences to us and our customers, including the development and implementation of tools incorporating artificial intelligence; pricing pressures on loans and deposits; our ability to successfully manage liquidity risk; changes in credit and other risks posed by the Company’s loan portfolio, including declines in commercial or residential real estate values or changes in the allowance for credit losses dictated by new market conditions, accounting standards or regulatory requirements; the concentration of large deposits from certain clients, including those who have balances above current FDIC insurance limits; the threat or imposition of domestic or foreign tariffs or other governmental policies impacting the global supply chain and the value of products produced by our commercial borrowers; effects on the U.S. economy resulting from actions taken by the federal government, including executive orders and immigration enforcement; changes in local, national and international economic conditions, including the level and impact of inflation, and future monetary policies of the Federal Reserve in response thereto, and possible recession; the impact of bank failures or adverse developments at other banks and related negative publicity about the banking industry in general on investor and depositor sentiment regarding the stability and liquidity of banks; changes in legal and regulatory requirements, limitations and costs; changes in customers’ acceptance of the Company’s products and services; the occurrence of fraudulent activity, breaches or failures of our or our third-party partners’ information security controls or cyber-security related incidents, including as a result of sophisticated attacks using artificial intelligence and similar tools; unexpected outcomes of existing or new litigation involving the Company; the monetary, trade and other regulatory policies of the U.S. government; the effects of acts of war or terrorism, including the wars in Iran and Ukraine and the military conflict between Israel and Hamas in the Middle East; widespread disease, pandemics or epidemics, or other adverse external events; risks related to climate change and the negative impact it may have on our customers and their business; changes to U.S. tax laws, regulations and guidance; potential changes in federal policy and at regulatory agencies; talent and labor shortages; and any other risks described in the “Risk Factors” sections of reports filed by the Company with the Securities and Exchange Commission (the “SEC”). The Company cautions readers not to place undue reliance on any forward-looking statements. Moreover, any of the forward-looking statements that the Company makes in this report or the documents the Company files with or furnishes to the SEC are based only on information then actually known to the Company and upon management’s beliefs and assumptions at the time they are made, which may turn out to be wrong because of inaccurate assumptions they might make, because of the factors described above or because of other factors that the Company cannot foresee. Forward-looking statements speak only as of the date they are made, and the Company does not undertake and specifically disclaims any obligation to revise or update such forward-looking statements to reflect current or future events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
		As of and for the Quarter Ended
KEY PERFORMANCE RATIOS AND OTHER METRICS		March 31, 2026				December 31, 2025				September 30, 2025				June 30, 2025				March 31, 2025
Return on average assets(1)			1.06	%			0.72	%			0.92	%			0.80	%			0.81	%
Return on average equity(2)			15.91				11.33				15.25				13.65				13.84
Net interest margin(3)(13)			2.59				2.47				2.36				2.27				2.28
Yield on interest-earning assets(4)(13)			5.04				5.02				5.13				5.07				5.04
Cost of interest-bearing liabilities			2.90				3.02				3.26				3.28				3.25
Efficiency ratio(5)(13)			49.85				50.21				54.06				56.45				56.37
Nonperforming assets to total assets(6)			0.00				0.00				0.00				0.00				0.00
ACL ratio(7)			1.02				1.02				1.01				1.03				1.01
Loans/total assets			74.59				72.47				75.50				73.12				75.66
Loans/total deposits			89.71				86.54				91.00				87.45				90.73
Tangible common equity ratio(8)			6.75				6.42				6.40				5.94				5.97
COMMON SHARE DATA
Earnings per common share (basic)		$	0.62			$	0.44			$	0.55			$	0.47			$	0.47
Earnings per common share (diluted)			0.61				0.43				0.55				0.47				0.46
Dividends per common share			0.25				0.25				0.25				0.25				0.25
Book value per common share(9)			15.90				15.70				15.06				14.22				14.06
Closing stock price			23.79				22.19				20.32				19.63				19.94
Market price/book value(10)			149.62	%			141.34	%			134.93	%			138.05	%			141.82	%
Price earnings ratio(11)			9.40				12.71				9.31				10.41				10.46
Annualized dividend yield(12)			4.20	%			4.51	%			4.92	%			5.09	%			5.02	%
REGULATORY CAPITAL RATIOS
Consolidated:
Total risk-based capital ratio			12.99	%			12.77	%			12.54	%			12.53	%			12.18	%
Tier 1 risk-based capital ratio			10.34				10.14				9.93				9.89				9.59
Tier 1 leverage capital ratio			8.74				8.44				8.51				8.33				8.36
Common equity tier 1 ratio			9.77				9.56				9.37				9.32				9.02
West Bank:
Total risk-based capital ratio			13.53	%			13.35	%			13.17	%			13.21	%			12.90	%
Tier 1 risk-based capital ratio			12.61				12.44				12.26				12.29				11.99
Tier 1 leverage capital ratio			10.66				10.35				10.50				10.36				10.46
Common equity tier 1 ratio			12.61				12.44				12.26				12.29				11.99

(1) Annualized net income divided by average assets.
(2) Annualized net income divided by average stockholders’ equity.
(3) Annualized tax-equivalent net interest income divided by average interest-earning assets.
(4) Annualized tax-equivalent interest income on interest-earning assets divided by average interest-earning assets.
(5) Noninterest expense (excluding other real estate owned expense and write-down of premises) divided by noninterest income (excluding net securities gains/losses and gains/losses on disposition of premises and equipment) plus tax-equivalent net interest income.
(6) Total nonperforming assets divided by total assets.
(7) Allowance for credit losses on loans divided by total loans.        
(8) Common equity less intangible assets (none held) divided by tangible assets.
(9) Includes accumulated other comprehensive loss.
(10) Closing stock price divided by book value per common share.
(11) Closing stock price divided by annualized earnings per common share (basic).
(12) Annualized dividend divided by period end closing stock price.
(13) A non-GAAP measure.

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		As of
CONDENSED BALANCE SHEETS		March 31, 2026				December 31, 2025				September 30, 2025				June 30, 2025				March 31, 2025
Assets
Cash and due from banks		$	40,018			$	25,171			$	26,875			$	35,796			$	39,253
Interest-earning deposits with banks			180,218				324,502				109,265				212,450				171,357
Securities purchased under agreements to resell			141,742				121,413				96,792				96,955				—
Securities available for sale, at fair value			456,410				468,447				537,856				536,709				546,619
Federal Home Loan Bank stock, at cost			15,180				15,167				15,190				15,311				15,216
Loans			2,991,638				3,001,690				3,008,888				2,966,357				3,016,471
Allowance for credit losses			(30,523	)			(30,525	)			(30,515	)			(30,539	)			(30,526	)
Loans, net			2,961,115				2,971,165				2,978,373				2,935,818				2,985,945
Premises and equipment, net			107,619				108,380				109,212				109,806				110,270
Bank-owned life insurance			46,500				46,192				45,875				45,567				45,272
Other assets			62,171				61,807				66,042				68,257				72,737
Total assets		$	4,010,973			$	4,142,244			$	3,985,480			$	4,056,669			$	3,986,669
Liabilities and Stockholders’ Equity
Deposits		$	3,334,972			$	3,468,470			$	3,306,517			$	3,391,993			$	3,324,518
Borrowings			375,221				376,406				389,076				390,260				391,445
Other liabilities			30,037				31,383				34,754				33,486				32,833
Stockholders’ equity			270,743				265,985				255,133				240,930				237,873
Total liabilities and stockholders’ equity		$	4,010,973			$	4,142,244			$	3,985,480			$	4,056,669			$	3,986,669
		For the Quarter Ended
AVERAGE BALANCES		March 31, 2026				December 31, 2025				September 30, 2025				June 30, 2025				March 31, 2025
Assets		$	4,027,218			$	4,104,279			$	4,004,769			$	4,016,490			$	3,944,789
Loans			2,971,497				2,982,754				2,959,962				2,989,638				3,016,119
Deposits			3,348,255				3,418,539				3,333,800				3,353,982				3,284,394
Stockholders’ equity			269,453				259,932				242,245				234,399				229,874

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		As of
LOANS		March 31, 2026				December 31, 2025				September 30, 2025				June 30, 2025				March 31, 2025
Commercial		$	471,423			$	505,059			$	511,316			$	500,854			$	531,267
Real estate:
Construction, land and land development			376,059				426,833				448,660				459,037				451,230
1-4 family residential first mortgages			139,118				93,122				87,784				86,173				86,292
Home equity			27,084				26,088				27,083				24,285				21,961
Commercial			1,958,189				1,929,766				1,912,235				1,875,857				1,909,330
Consumer and other			22,257				23,374				24,697				22,900				19,323
			2,994,130				3,004,242				3,011,775				2,969,106				3,019,403
Net unamortized fees and costs			(2,492	)			(2,552	)			(2,887	)			(2,749	)			(2,932	)
Total loans		$	2,991,638			$	3,001,690			$	3,008,888			$	2,966,357			$	3,016,471
Less: allowance for credit losses			(30,523	)			(30,525	)			(30,515	)			(30,539	)			(30,526	)
Net loans		$	2,961,115			$	2,971,165			$	2,978,373			$	2,935,818			$	2,985,945
CREDIT QUALITY
Pass		$	2,952,824			$	2,952,015			$	2,973,103			$	2,958,318			$	3,011,231
Watch			41,306				52,227				38,672				10,788				7,991
Substandard			—				—				—				—				181
Doubtful			—				—				—				—				—
Total loans		$	2,994,130			$	3,004,242			$	3,011,775			$	2,969,106			$	3,019,403
DEPOSITS
Noninterest-bearing demand		$	511,013			$	540,358			$	512,869			$	521,990			$	519,771
Interest-bearing demand			489,990				577,814				448,731				461,207				517,409
Savings and money market – non-brokered			1,731,835				1,739,790				1,677,543				1,749,049				1,490,189
Money market – brokered			86,304				99,718				121,849				98,877				143,423
Total nonmaturity deposits			2,819,142				2,957,680				2,760,992				2,831,123				2,670,792
Time – non-brokered			485,658				455,944				462,542				451,463				461,655
Time – brokered			30,172				54,846				82,983				109,407				192,071
Total time deposits			515,830				510,790				545,525				560,870				653,726
Total deposits		$	3,334,972			$	3,468,470			$	3,306,517			$	3,391,993			$	3,324,518
BORROWINGS
Subordinated notes, net		$	80,221			$	80,156			$	80,090			$	80,024			$	79,959
Federal Home Loan Bank advances			270,000				270,000				270,000				270,000				270,000
Long-term debt			25,000				26,250				38,986				40,236				41,486
Total borrowings		$	375,221			$	376,406			$	389,076			$	390,260			$	391,445
STOCKHOLDERS’ EQUITY
Preferred stock		$	—			$	—			$	—			$	—			$	—
Common stock			3,000				3,000				3,000				3,000				3,000
Additional paid-in capital			36,553				37,231				36,473				35,773				35,072
Retained earnings			300,596				294,259				291,069				285,990				282,247
Accumulated other comprehensive loss			(69,406	)			(68,505	)			(75,409	)			(83,833	)			(82,446	)
Total stockholders’ equity		$	270,743			$	265,985			$	255,133			$	240,930			$	237,873

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		For the Quarter Ended
CONSOLIDATED STATEMENTS OF INCOME		March 31, 2026			December 31, 2025				September 30, 2025			June 30, 2025			March 31, 2025
Interest income:
Loans, including fees		$	40,946		$	41,992			$	42,198		$	41,666		$	40,988
Securities:
Taxable			2,143			2,355				2,643			2,685			2,788
Tax-exempt			638			677				739			742			743
Deposits with banks			2,047			2,808				2,087			2,847			1,617
Securities purchased under agreements to resell			1,617			1,370				1,258			22			—
Total interest income			47,391			49,202				48,925			47,962			46,136
Interest expense:
Deposits			19,261			21,112				22,539			22,676			21,423
Subordinated notes			1,104			1,109				1,107			1,104			1,105
Federal Home Loan Bank advances			2,244			2,316				2,292			2,259			2,235
Long-term debt			397			459				486			504			518
Total interest expense			23,006			24,996				26,424			26,543			25,281
Net interest income			24,385			24,206				22,501			21,419			20,855
Credit loss expense			—			—				—			—			—
Net interest income after credit loss expense			24,385			24,206				22,501			21,419			20,855
Noninterest income:
Service charges on deposit accounts			508			493				491			486			471
Debit card interchange income			472			493				477			478			446
Trust services			1,010			964				894			801			777
Increase in cash value of bank-owned life insurance			308			317				308			295			282
Realized securities losses, net			—			(3,959	)			—			—			—
Other income			256			800				333			350			267
Total noninterest income (loss)			2,554			(892	)			2,503			2,410			2,243
Noninterest expense:
Salaries and employee benefits			7,632			7,579				7,457			7,343			7,004
Occupancy and equipment			2,006			2,083				2,090			2,034			1,963
Data processing			596			673				663			643			617
Technology and software			774			789				794			791			786
FDIC insurance			473			475				637			670			587
Professional fees			278			297				303			303			308
Other expenses			1,706			1,833				1,606			1,701			1,798
Total noninterest expense			13,465			13,729				13,550			13,485			13,063
Income before income taxes			13,474			9,585				11,454			10,344			10,035
Income taxes			2,902			2,160				2,140			2,365			2,193
Net income		$	10,572		$	7,425			$	9,314		$	7,979		$	7,842
Basic earnings per common share		$	0.62		$	0.44			$	0.55		$	0.47		$	0.47
Diluted earnings per common share		$	0.61		$	0.43			$	0.55		$	0.47		$	0.46

NON-GAAP FINANCIAL MEASURES

This report contains references to financial measures that are not defined in GAAP. Such non-GAAP financial measures include the Company’s presentation of net interest income and net interest margin on a fully taxable equivalent (FTE) basis and the presentation of the efficiency ratio on an adjusted and FTE basis, excluding certain income and expenses. Management believes these non-GAAP financial measures provide useful information to both management and investors to analyze and evaluate the Company’s financial performance. These measures are considered standard measures of comparison within the banking industry. Additionally, management believes providing measures on a FTE basis enhances the comparability of income arising from taxable and nontaxable sources. Limitations associated with non-GAAP financial measures include the risks that persons might disagree as to the appropriateness of items included in these measures and that different companies might calculate these measures differently. These non-GAAP disclosures should not be considered an alternative to the Company’s GAAP results. The following table reconciles the non-GAAP financial measures of net interest income and net interest margin on a fully taxable equivalent basis and efficiency ratio on an adjusted and FTE basis.

(in thousands)		For the Quarter Ended
		March 31, 2026				December 31, 2025				September 30, 2025				June 30, 2025				March 31, 2025
Reconciliation of net interest income and net interest margin on a FTE basis to GAAP:
Net interest income (GAAP)		$	24,385			$	24,206			$	22,501			$	21,419			$	20,855
Tax-equivalent adjustment(1)			72				70				61				59				66
Net interest income on a FTE basis (non-GAAP)			24,457				24,276				22,562				21,478				20,921
Average interest-earning assets			3,821,463				3,893,827				3,790,154				3,799,081				3,717,441
Net interest margin on a FTE basis (non-GAAP)			2.59	%			2.47	%			2.36	%			2.27	%			2.28	%
Reconciliation of efficiency ratio on an adjusted and FTE basis to GAAP:
Net interest income on a FTE basis (non-GAAP)		$	24,457			$	24,276			$	22,562			$	21,478			$	20,921
Noninterest income			2,554				(892	)			2,503				2,410				2,243
Adjustment for realized securities losses, net			—				3,959				—				—				—
Adjustment for losses on disposal of premises and equipment, net			2				—				—				—				8
Adjusted income			27,013				27,343				25,065				23,888				23,172
Noninterest expense			13,465				13,729				13,550				13,485				13,063
Efficiency ratio on an adjusted and FTE basis (non-GAAP)(2)			49.85	%			50.21	%			54.06	%			56.45	%			56.37	%

(1) Computed on a tax-equivalent basis using a federal income tax rate of 21 percent, adjusted to reflect the effect of the nondeductible interest expense associated with owning tax-exempt securities and loans. Management believes the presentation of this non-GAAP measure provides supplemental useful information for proper understanding of the financial results, as it enhances the comparability of income arising from taxable and nontaxable sources. 
(2) The efficiency ratio expresses noninterest expense as a percent of fully taxable equivalent net interest income and noninterest income, excluding specific noninterest income and expenses. Management believes the presentation of this non-GAAP measure provides supplemental useful information for proper understanding of the Company’s financial performance. It is a standard measure of comparison within the banking industry. A lower ratio is more desirable.

For more information contact:
Jane Funk, Executive Vice President, Treasurer and Chief Financial Officer (515) 222-5766

• The Bitcoin Bonus Program is a powerful, new benefit option for employers
• Steak ’n Shake flagship partnership offers the Bitcoin Bonus Program to thousands of hourly employees

PHOENIX, April 23, 2026 (GLOBE NEWSWIRE) — Fold Holdings, Inc. (NASDAQ: FLD) (“Fold” or the “Company”), a bitcoin financial services company making it easy for individuals to earn, save and spend bitcoin through everyday financial tools, today announced the Bitcoin Bonus Program, an easy-to-use employee bonus program that lets employers deliver recurring bitcoin bonuses with built-in vesting without changing payroll systems or taking on custody or compliance responsibilities.

The Bitcoin Bonus Program is the first offering from Fold Business, a first of its kind, B2B bitcoin financial platform that extends Fold’s best-in-class bitcoin financial tools to businesses and their employees. Implementation is simple; employers designate USD bonus amounts on their existing payroll cadence and Fold does the rest; Bitcoin conversion, custody, vesting administration, and employee-facing delivery through the Fold app. No prior Bitcoin knowledge is required.

Unlike typical cash bonuses that often disappear into everyday expenses or one-time purchases, the Bitcoin Bonus Program taps into bitcoin’s value as a long-term asset that employees can track, hold, and grow over time. When paired with a vesting structure, the Bitcoin Bonus Program can transform a traditional bonus into a retention mechanic. A reason to stay, not just a bonus for having stayed.

“We launched our Bitcoin Bonus Program because we saw a gap that no one was filling,” said Will Reeves, CEO and Co-Founder of Fold. “An employer-grade bonus vehicle that’s differentiated enough to matter, accessible enough for every employee, and operationally simple enough that HR and Finance don’t need to become bitcoin experts to run it. We’ve created a recruiting story that didn’t exist before.”

Fold’s flagship Bitcoin Bonus Program partner, Steak ’n Shake, employs over 10,000 workers across the United States. Through its program with Fold, Steak ‘n Shake is enabling these employees to earn bitcoin as part of their compensation experience. Simple Mining, a leading bitcoin mining hosting company based in Cedar Falls, Iowa, is also using the Bitcoin Bonus Program to reward its salaried workforce with recurring bitcoin allocations tied to tenure.

“Employee bonus programs haven’t changed in decades,” said Matt Garland, Head of Revenue, at Simple Mining. “Cash hits an account and it’s gone by Friday. SimpleMining hosts Bitcoin miners for investors, and our team sees the value of this asset up close every single day. We want to help them accumulate it. Allocating 1% of every employee’s pay into Bitcoin, redeemable at year-end, lets our team share in that upside. The bonus grows with time, and so does the reason to stick around.”

“What Steak ‘n Shake and Simple Mining show is that this isn’t a niche product for one type of company,” added Reeves. “A 10,000-person hourly workforce and a specialized mining operation are using the same program, configured for how they actually work. That’s what we built Fold Business to do. The employer sets the terms in dollars. Fold handles everything else.”

Fold’s bonus program can be especially attractive to companies with large hourly workforces at QSR chains, retail and service industries. It is also a differentiated option for tech-forward employers looking to entice and retain valuable salaried employees with more than the typical equity and cash incentives to create longer-term employee alignment.

Bonuses are just the beginning for Fold Business. Over time, the Company aims to extend the Fold Business platform to include payroll, corporate bitcoin treasury management, corporate cards, and additional enterprise financial tools built on bitcoin.

About Fold

Fold (NASDAQ: FLD) is the first publicly traded bitcoin financial services company, making it easy for individuals and businesses to earn, save, and use bitcoin. Fold is at the forefront of integrating bitcoin into everyday financial experiences. Through innovative products like the Fold App, Fold Credit Card™, Fold Bitcoin Gift Card™, and Fold Debit Card™, the company is building the bridge between traditional finance and the bitcoin-powered future.

For investor inquiries, please contact:

Orange Group
Samir Jain, CFA
[email protected]

For media inquiries, please contact:

Cindy Stoller
Confluence Partners, LLC
917-331-0418
[email protected]
[email protected]

Cautionary Note on Forward-Looking Statements

The information in this letter includes “forward-looking statements” within the meaning of the federal securities laws. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements may be identified by the use of words such as “may,” “could,” “would,” “should,” “predict,” “estimate,” “plan,” “aim,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on assumptions and on the current expectations of Fold’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of Fold. These forward-looking statements are subject to a number of risks and uncertainties, including: (i) our continued ability to implement business plans, including but not limited to our ability to make technical updates and other product upgrades; (ii) access to and reliance on funding for our products; (vi) access to and reliance on third parties, including banking partners; and (viii) those risks and uncertainties discussed in Fold Holding, Inc.’s filings with the Securities and Exchange Commission, including, but not limited to our previous Annual Report on Form 10-K and our subsequent Quarterly Reports. If any of these risks materialize or Fold’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Fold may elect to update these forward-looking statements at some point in the future, Fold specifically disclaims any obligation to do so, except as required by law.

Preliminary Q1 2026 Revenue up more than 2x Sequentially to Approximately $2.4 Million

Expansion into Tier 3 AI/HPC Data Center Infrastructure is Underway

WEST PALM BEACH, FL, April 23, 2026 (GLOBE NEWSWIRE) — AVAX One Technology Ltd. (Nasdaq: AVX) (“AVAX One” or the “Company”), today announced preliminary financial and operational results for the three months ended March 31, 2026.

Preliminary Q1 2026 Revenue and Liquidity Highlights

Based on preliminary results for the quarter ended March 31, 2026, the Company expects to report a revenue increase of more than double to $2.4 million compared to Q4 2025. The increase was primarily driven by increased Avalanche staking rewards and Bitcoin mining revenue. In addition, AVAX One is reporting a total cash balance of $27.2 million, which provides the Company with more than adequate liquidity to fund operating costs for more than three years without liquidating any of its digital assets.

Operational Highlights

• Executed a Letter of Intent to develop an initial 10 MW Tier 3-ready AI/HPC powered land site in Alberta, with expected readiness for end-client deployment in Q1 2027, marking the Company’s formal expansion into data center infrastructure and positioning AVAX One to capitalize on accelerating demand for compute capacity and energy-advantaged digital infrastructure. The Company has already undertaken the next steps following the LOI and has initiated the formal due diligence process, including retention of counsel in Alberta, and is in the final stages of choosing the engineering firm for the project.
• Increased Bitcoin mining capacity to ~250 PH/s, with near-term expansion expected to exceed 300 PH/s within the next 30 days, reflecting continued investment in scalable, energy-efficient compute infrastructure.
• Expanded Avalanche digital asset treasury to approximately 14.0 million AVAX, with over 90% actively staked, generating a ~6% annualized yield and reinforcing the Company’s focus on yield-generating onchain assets.
• Achieved a current annualized revenue run rate of over $11.0 million, with more than $7.0 million from AVAX staking rewards and over $4.0 million from Bitcoin mining operations, based on current digital asset prices.

“Our first quarter results underscore the early success of our enhanced model that generates increased operating cash flows resulting from our diversified revenue strategy,” said Jolie Kahn, Chief Executive Officer of AVAX One. “Avalanche ranks among the most high-performing and scalable blockchain ecosystems worldwide, delivering compelling yields supported by structural scarcity from its capped supply and transaction fee burns. AVAX One was designed as the preeminent public gateway providing investors with direct, leveraged exposure to Avalanche’s continued expansion. By staking over 90% of our AVAX tokens, we generate a steady annualized yield of approximately 6%. This approach enables us to compound AVAX per share and establish a scalable, recurring revenue foundation linked to the long-term development of the Avalanche ecosystem and the increasing institutional embrace of digital assets.”

The Company continues to expand its development of the physical infrastructure required for digital compute, which is in high demand. AVAX One recently announced a Letter of Intent to develop a 10 MW Tier 3-ready powered land site in Alberta that utilizes natural gas generation behind-the-meter and is targeting Q1 2027 readiness. This investment allows the Company to own one of the critical constraints facing AI/HPC data center development: access to consistent power. The micro-grid, modular data center design powered by existing natural gas is in demand because of significantly shorter deployment timeframe, lower capital commitments, and ability to scale. Ultimately, this dual strategy positions AVAX One as one of the only publicly traded companies to own access to the scarce resources that are driving the future of digital finance and AI development.

Full Year 2026 Guidance

The Company is reiterating its previously issued guidance:

($ in Millions USD)	Current Spot Price 1	2025 Avg. Price 2	2025 High Price 3
Revenue	$11M – $12M	$24M – $25M	$43M – $44M
Change vs. prior year period	~5x	~10x	~19x
EBITDA 4	$2M – $3M	$10M – $11M	$24M – $25M

About AVAX One Technology Ltd.

AVAX One Technology Ltd. (NASDAQ: AVX) is the first publicly traded Avalanche Treasury company, building the premier institutional gateway to the onchain financial economy powered by the Avalanche blockchain network. Through AVAX accumulation, onchain yield, and strategic acquisitions, the Company aims to compound long-term value for its shareholders while supporting the growth of the Avalanche ecosystem. Led by a team of veterans from institutional finance and public company backgrounds and advised by leaders from across the digital asset industry, AVAX One is being built to be a scalable, regulated gateway for public market investors to participate in the growth of the onchain economy. For more information, visit www.avax-one.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters including statements relating to the anticipated benefits and timing of the completion of the proposed offering and related transactions, the intended use of proceeds from the PIPE offering, expectations regarding future capital raising activity, the assets to be held by the Company, expectations regarding adoption of the Avalanche network, the expected future market, price and liquidity of the digital assets the Company acquires, the macro and political conditions surrounding digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other entities in similar business strategies, technological and market trends, future financial condition and performance, the expected financial impacts of the proposed transactions described herein, and the timing of the closing of the PIPE offering. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the proposed transactions described herein may not be completed in a timely manner or at all; failure to realize the anticipated benefits of the transactions and the proposed AVAX strategy; changes in business, market, financial, political and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price of AVAX and other cryptocurrencies; the risk that the price of the Company’s securities may be highly correlated to the price of the digital assets that it holds; risks related to increased competition in the industries and markets in which the Company does and will operate (including the applicable digital assets market); risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes, as well as those risks and uncertainties identified in the Company’s filings with the SEC. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. The statements made in this press release are not intended to be projections of the Company’s future results nor an offer of a future securities transaction by the Company. Any offering in the future will be made through compliance with all applicable regulations and the filing of appropriate documents with the SEC, as required under those regulations.

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

Media Contact

Ethan Lyle
Prospero
[email protected]

Reconciliation of GAAP and Non-GAAP Information

($ in Millions, unaudited)

Full Year 2026 Guidance Scenarios
($ in millions)			Current Spot Price				2025 Avg. Price				2025 High Price
Revenue		$	11.4			$	24.2			$	43.3
Total operating expenses			10.6				14.9				20.3
Operating income			0.9				9.4				23.0
Other expenses			0.8				0.8				0.8
Net income from continuing operations			0.1				8.6				22.3
EBITDA Adjustments:
Depreciation and amortization			1.3				1.3				1.3
Accretion of interest on debentures			0.8				0.8				0.8
EBITDA			2.2				10.7				24.3

---

¹ Assumes Bitcoin price of ($70,000.00) and Avalanche price of ($9.00).
² Assumes Bitcoin price of ($101,877.40) and Avalanche price of ($22.43).
³ Assumes Bitcoin price of ($124,720.00) and Avalanche price of ($44.10).
⁴ The tables at the end of this press release provide a reconciliation of non-GAAP financial measures to the Company’s expected results in accordance with GAAP. (See “Reconciliation of GAAP and non-GAAP Information” below).

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until May 7, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 244506.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid^® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
[email protected]
+1 (734) 418-4411

To be effective April 27, 2026

Aiming to meet the minimum bid price requirement for maintaining listing on Nasdaq

ATHENS, Greece, April 23, 2026 (GLOBE NEWSWIRE) — C3is Inc. (the “Company”) (Nasdaq: CISS) today announced that its board of directors has determined to effect a one-for-seven (1-for-7) reverse stock split of the Company’s common stock, par value $0.01 per share.

The reverse stock split will take effect at 11:59 pm Eastern Time on April 26, 2026, and the Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) as of the opening of trading on April 27, 2026. The CUSIP number of Y18284300 will be assigned to the Company’s common stock when the reverse stock split becomes effective.

When the reverse stock split becomes effective, every seven (7) of the Company’s issued shares of common stock will be combined into one issued share of common stock, without any change to the par value per share. This will reduce the number of outstanding shares of common stock from approximately 3.7 million shares to approximately 528,305 shares. The Company’s outstanding warrants and Series A Convertible Preferred Stock will be proportionately adjusted to increase the exercise price and reduce the number of shares issuable upon exercise. With respect to the Company’s Class B Warrants and Class C Warrants, the exercise price and number of shares issuable upon exercise will be adjusted further in an adjustment period ending on the fifth trading day after the effective time of the reverse split pursuant to the terms of such warrants.

No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fraction of a share of common stock of the Company will receive a cash payment in lieu thereof at a price equal to that fraction of a share to which the stockholder would otherwise be entitled, multiplied by the closing price of the Company’s common stock on Nasdaq on April 24, 2026 (as adjusted for the reverse split).

Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after April 27, 2026. Such beneficial holders may contact their bank, broker, or nominee for more information.

The reverse stock split ratio approved by the board of directors is within the range of ratios for a reverse stock split authorized by the stockholders of the Company.

The purpose of the reverse stock split is to increase the market price of the Company’s common stock. The Company believes that the reverse stock split will increase the market price for its common stock and allow it to satisfy the minimum bid price requirement for maintaining listing on Nasdaq.

Forward-Looking Statements

Matters discussed in this release may constitute forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the C3is Inc.’s ability to maintain compliance with Nasdaq’s continued listing standards and remain listed on Nasdaq or other major stock exchange and other statements that are forward-looking. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. The forward-looking statements in this release are based upon various assumptions. Although C3is Inc. believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, C3is Inc. cannot assure you that it will achieve or accomplish these expectations, beliefs or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include risks discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). Risks and uncertainties are further described in reports filed by C3is Inc. with the SEC.

ABOUT C3IS INC.

C3is Inc. is a ship-owning company providing dry bulk and crude oil seaborne transportation services. The Company currently owns five vessels, comprising three Handysize dry bulk carriers with a total capacity of 97,664 deadweight tons (dwt), an Aframax oil tanker with a cargo carrying capacity of 115,804 dwt and a product tanker with a cargo carrying capacity of 47,203 dwt, resulting in a fleet total capacity of 260,671 dwt. On a pro forma basis following the delivery of one additional MR product tanker, the Company’s fleet will consist of six vessels: three Handysize dry bulk carriers, one Aframax tanker, and two MR product tankers, with a total carrying capacity of approximately 311,431 dwt. C3is Inc.’s shares of Common Stock are listed on the Nasdaq Capital Market and trade under the symbol “CISS.”

For further information, please contact:

Company Contact:

Nina Pyndiah
Chief Financial Officer
C3is Inc. 
00-30-210-6250-001  
E-mail: [email protected]

WILMINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) — Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, today announced it has become an approved partner in the U.S. Department of War (DoW) SkillBridge program. 

The DoW SkillBridge program allows active-duty service members to gain civilian work experience through specific industry training, apprenticeships, or internships during their final 180 days of service, while continuing to receive military pay and benefits.

At Symbotic, participants will take part in on-the-job training designed to help them explore opportunities across the organization, many of which will be a natural fit for service members who have led teams, managed complex operations, and maintained critical systems in fast-paced environments. 

“As a veteran, this collaboration is personally meaningful to me,” said Pete Opalacz, Senior Vice President, Customer Operations at Symbotic. “Transitioning from military service into the civilian workforce can be challenging. We’re excited to connect with service members during this pivotal moment, to help facilitate those transitions and introduce to Symbotic proven problem-solvers with strong leadership and technical capabilities who have the potential to make a powerful impact across our operations.”

“Service members bring a strong sense of mission and accountability that aligns closely with Symbotic’s culture, and we’re proud to be part of this program,” said Miriam Ort, Chief Human Resources & Growth Officer at Symbotic. “We look forward to working with SkillBridge participants to help them translate their strengths and skills into meaningful private-sector work, and to the opportunity to learn from each other.”

For more information about the DoW SkillBridge program, visit skillbridge.osd.mil. To explore opportunities at Symbotic, visit our Careers page.

ABOUT SYMBOTIC 

Symbotic is an automation technology leader reimagining the supply chain with its end-to-end, A.I.-powered robotic and software platform. Symbotic reinvents the warehouse as a strategic asset for the world’s largest retail, wholesale, food & beverage, and medical supply distribution companies. Applying next-generation technology, high-density storage and machine learning to solve today’s complex distribution challenges, Symbotic enables companies to move goods with unmatched speed, agility, accuracy and efficiency. As the backbone of commerce Symbotic transforms the flow of goods and the economics of the supply chain for its customers. For more information, visit www.symbotic.com.

Media Contact

Matt Buckley 
Vice President, Communications 
[email protected] 

Investor Relations Contact

Charlie Anderson
Vice President, Investor Relations & Corporate Development
[email protected]

CHICAGO, April 23, 2026 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that it will release its results for the first quarter 2026 on Thursday, May 7, 2026.

Management will host a webcast and conference call on May 7, 2026, at 10:00 a.m. ET to discuss the results and provide a business update. The conference call will be available via public webcast through the Public Shareholders section of GCM Grosvenor’s website at
www.gcmgrosvenor.com/public-shareholders and a replay will be available on the website soon after the call’s completion for at least seven (7) days.

To register for the call, visit www.gcmgrosvenor.com/public-shareholders.

About GCM Grosvenor

GCM Grosvenor (Nasdaq: GCMG) is a global alternative asset management solutions provider with approximately $91 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute return investment strategies. The firm has specialized in alternatives for more than 50 years and is dedicated to delivering value for clients by leveraging its cross-asset class and flexible investment platform. 

GCM Grosvenor’s experienced team of approximately 550 professionals serves a global client base of institutional and individual investors. The firm is headquartered in Chicago, with offices in New York, Toronto, London, Frankfurt, Tokyo, Hong Kong, Seoul and Sydney. For more information, visit: gcmgrosvenor.com.

Source: GCM Grosvenor

Public Shareholders Contact

Stacie Selinger
[email protected]
312-506-6583

Media Contact

Abigail Ruck
H/Advisors Abernathy
[email protected]
212-371-5999